Results 111 to 120 of about 5,953 (226)

Sustained Virologic Response Rates of Sofosbuvir and Velpatasvir in Patients with Hepatitis C Genotype 3: A Meta-Analysis

, 2020
Xi Ran, HuaiYi Xie, Wei Li
openalex   +2 more sources

Correction to: Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation [PDF]

, 2022

openalex   +1 more source

Issue Information

The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 11, November 2025.
wiley   +1 more source

Аддитивные технологии: применение в медицине и фармации [PDF]

, 2019
ТЕХНОЛОГИЯ МЕДИЦИНСКАЯ /ОБОРУД /ТЕНДЕНЦИИФАРМАЦИЯ /ОБОРУД /ТЕНДЕНЦИИАДДИТИВНЫЕ ТЕХНОЛОГИИМЕТОДЫ 3D-ПЕЧАТИТЕХНОЛОГИЙ РАСПРОСТРАНЕНИЕОБЗОР ЛИТЕРАТУРЫПроведен обзор современного состояния вопроса использования аддитивных технологий в медицине и ...
Малаев, И. А., Пивовар, М. Л.   +1 more
core  

Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan

, 2020
Chen‐Hua Liu, Tung‐Hung Su, Chun‐Jen Liu, Pei‐Jer Chen, Ding‐Shinn Chen, Jia‐Horng Kao   +5 more
openalex   +1 more source

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection [PDF]

, 2018
Johann von Felden, Johannes Vermehren, Patrick Ingiliz, Stefan Mauss, Thomas A. Lutz, Karl‐Georg Simon, H. Busch, Axel Baumgarten, Knud Schewe, D. Hueppe, Christoph Boesecke, JK Rockstroh, Martin Daeumer, Nadine Luebke, Jörg Timm, Julian Schulze zur Wiesch, Christoph Sarrazin, Stefan Christensen   +17 more
openalex   +1 more source

To assess the drug safety and efficacy of sofosbuvir plus velpatasvir in hepatitis C patients

, 2020
Nikhil Reddy C, Bala Krishna K, Narender Boggula, Sadhana Kanukuntla, Vasudha Bakshi, Vivek Kumar Kunduru   +5 more
openalex   +1 more source

An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences

Pathogens
Direct-acting antivirals (DAAs) revolutionized the therapeutics of chronic hepatitis C. The emergence and transmission of HCV variants with resistance-associated substitutions (RASs) can undermine HCV treatment.
Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, Malik Sallam   +3 more
doaj   +1 more source

Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure [PDF]

Background & Aims: Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for re-treatment of direct-acting antiviral (DAA)-experienced patients with chronic HCV infection.
Buti, Maria, D'Ambrosio, Roberta, Degasperi, Elisabetta, Dietz, Julia, Dultz, Georg, Finkelmeier, Fabian, Graf, Christiana, Herrmann, Eva, Lampertico, Pietro, Llaneras, Jordi, Paolucci, Stefania, Peiffer, Kai-Henrik, Sarrazin, Christoph, Vermehren, Johannes, Zeuzem, Stefan   +14 more
core   +1 more source

Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers [PDF]

, 2018
Erik Mogalian, Luisa M. Stamm, Anu Osinusi, Diana M. Brainard, Gong Shen, Kah Hiing John Ling, Anita Mathias   +6 more
openalex   +1 more source